TiumBio (KOSDAQ: 321550) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for patients with rare and incurable diseases. Our mission is to enhance the hope and happiness of humanity through scientific advancements. TiumBio currently has three leading pipeline assets in clinical trials, with TU2218 being investigated in Phase 2 and TU2670 and TU7710 in Phase 1. TU2218 is an oral immuno-oncology therapy targeting TGF-beta and VEGFR2, while TU2670 is an orally active non-peptide GnRH antagonist. Additionally, TU7710 is a bypass-factor treatment specifically designed for hemophilia patients who have developed neutralizing antibodies.

TiumBio is located in Seongnam-si, South Korea and has three subsidiaries including Boston-based biotechnology company, Initium Therapeutics and a CDO compnay, Protium Science.

For any media inquiry or investor relations, contact ir@tiumbio.com

TiumBio

Org chart

Teams

Offices